A study of ASP2138 given by itself or given with other cancer treatments in adults with stomach cancer, gastroesophageal junction cancer, or pancreatic cancer
2138-CL-0101
Phase 1 other active
Quick answer
A study of ASP2138 given by itself or given with other cancer treatments in adults with stomach cancer, gastroesophageal junction cancer, or pancreatic cancer for Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma is a Phase 1 program (other) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Astellas Pharma GmbH
- Indication
- Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma
- Phase
- Phase 1
- Modality
- other
- Status
- active